Guillain-Barre syndrome during COVID-19 pandemic. Case reports
Keywords:
Guillain-Barre Syndrome, COVID-19, vaccinesAbstract
Guillain-Barré syndrome often develops as an immune reaction after exposure to certain viral or bacterial antigens, or vaccines. Increasing number of cases have been reported developing during COVID-19 infection, with neurological symptoms beginning on average about 9 days after the onset of the respiratory disease. Isolated cases of Guillain-Barré syndrome have been reported after recovering from COVID-19, and it is hypothesized that the syndrome differs in pathogenesis depending on the time of developing neurological manifestation in the course of the main infectious process. The incidence of Guillain-Barré syndrome has also increased following SARS-Cov-2 vaccination, mainly following the ChAdOx1nCoV-19 vaccine. Despite increasing the risk after vaccination, the risk of developing neurological complications, including Guillain-Barré syndrome, after a positive SARSCoV-2 test remains significantly higher. We present two cases of Guillain-Barré syndrome – the first one – after recovering from COVID-19 and the second one – after vaccination.
References
Sansone, P., Giaccari, L., Aurilio, C., Coppolino, F., Esposito, V., Fiore, M., Paladini, A., Passavanti,M., Pota, V., Pace, M., Rampias, T. Post-Infectious Guillain-Barré Syndrome Related to SARS-CoV-2 Infection: A Systematic Review. Life, 2021, 11, 167. doi.org/10.3390/life11020167.
Introna, A., Caputo, F., Santoro, C., Guerra, T., Ucci, M., Mezzapesa, D., Trojano, M. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Clin Neurol Neurosurg, 2021, 208: 106887. doi: 10.1016/j.clineuro.2021.106887.
Raahimi, M., Kane, A., Moore, C., Alareed, A. Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of ‘long COVID-19 syndrome’? BMJ Case Rep, 2021, Jan 18, 14, 1, e240178. doi: 10.1136/bcr-2020-240178.
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., Chang, J., Hong, C., Zhou, Y., Wang, D., Miao, X., Li, Y., Hu, B. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol, 2020, 77, 6, 683-690. doi:10.1001/jamaneurol.2020.1127.
Shoraka, S., Ferreira, M., Mohebbi, S., Ghaemi, A. SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms. Front Immunol, 2021, May, 10, 12, 674922. doi: 10.3389/fimmu.2021.674922.
The National Institute for Health and Care Excellence (NICE) guideline [NG188]. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Published, 18 December, 2020, 1-106, Last updated: 11 November 2021.
Taquet, M., Geddes, J., Husain, M., Luciano, S., Harrison P. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry, April, 2021, 8, 5. doi: 10.1016/S2215-0366(21)00084-5.
Goss, A., Samudralwar, R., Das, R., Nath, A. ANA Investigates: Neurological Complications of COVID-19 Vaccines. Ann Neurol, 2021 May, 89, 5, 856-857. doi: 10.1002/ana.26065. Epub 2021 Mar 30.
Misra, S., Kolappa, K., Prasad, M., Radhakrishnan, D., Thakur, K., Solomon, T., Michael, B., Winkler, A., Beghi , E., Guekht, A., Pardo, C., Wood, G., Chou, S., Fink, E.,Schmutzhard, E., Kheradmand, A., Hoo, F., Kumar, A., Das, A., Srivastava, A., Agarwal, A., Dua, T., Prasad, K. Frequency of neurological manifestations in COVID-19: a systematic review and meta-analysis of 350 studies. Neurology, 2021 Oct, 11, doi: 10.1212/WNL.0000000000012930.
Flemming, A. Comparing neurological complications after COVID-19 vaccination and SARS-CoV-2 infection. Nat Rev Immunol, 2021 Nov 5, 1. doi: 10.1038/s41577-021-00655-3.
Downloads
Published
How to Cite
Issue
Section
ARK
License
Copyright (c) 2021 Bulgarian Neurology
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
